| Not Yet Recruiting | Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line NCT07537777 | Nanfang Hospital, Southern Medical University | Phase 2 |
| Not Yet Recruiting | Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer(TitAN) : NCT07089199 | Qilu Hospital of Shandong University | Phase 2 |
| Not Yet Recruiting | Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC NCT06699498 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Withdrawn | Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer NCT04620473 | Shanghai Minimally Invasive Surgery Center | Phase 2 |
| Not Yet Recruiting | A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positi NCT06048315 | Degan Lu | Phase 3 |
| Not Yet Recruiting | Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR NCT05778149 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Unknown | Anlotinib and Radiotherapy in Resectable Soft Tissue Sarcoma NCT05602415 | Ruijin Hospital | Phase 2 |
| Unknown | Niraparib Plus Anlotinib for Recurrent Ovarian Cancer NCT05311579 | Lei Li | Phase 2 |
| Unknown | Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma NCT05030077 | Tianjin Medical University Second Hospital | Phase 2 |
| Active Not Recruiting | Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cance NCT04807166 | Wenjun Cheng | Phase 2 |
| Unknown | Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer NCT04803851 | Peking Union Medical College Hospital | Phase 1 / Phase 2 |
| Unknown | Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC NCT04665609 | Chinese PLA General Hospital | Phase 3 |
| Unknown | SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer NCT04797507 | Peking Union Medical College Hospital | Phase 2 |
| Active Not Recruiting | Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSC NCT05400070 | Tang-Du Hospital | Phase 2 |
| Unknown | Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer NCT04566952 | Xiaoxiang Chen | Phase 2 |
| Completed | Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC) NCT04271813 | Shanghai Changzheng Hospital | Phase 2 |
| Recruiting | Preoperative IMRT With Concurrent Anlotinib for Localised Extremity or Trunk Sarcoma （SPARE-01） NCT05167994 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Unknown | Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence NCT04213118 | First Affiliated Hospital Xi'an Jiaotong University | Phase 2 |
| Unknown | Anlotinib In Combination With PD-1/L1 Inhibitor As Sequential Therapy of Thoracic Radiotherapy After Induction NCT04313660 | Xiaorong Dong | Phase 2 |
| Unknown | Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemot NCT04314297 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 |
| Recruiting | Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC) NCT04278222 | Shanghai Changzheng Hospital | Phase 2 |
| Unknown | A Single-arm, Phase Ⅱ Clinical Trial of Anlotinib Hydrochloride Combined With Irinotecan or Docetaxel for Seco NCT04757779 | First People's Hospital of Hangzhou | Phase 2 |
| Unknown | Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC NCT04116918 | Baodong Qin | — |
| Unknown | Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung Cancer NCT04684017 | Shanghai Chest Hospital | Phase 2 |
| Completed | Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer NCT04012619 | Sichuan University | Phase 1 |
| Completed | Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma NCT03936452 | Sun Yat-sen University | Phase 2 |
| Unknown | Anlotinib Plus Chemotherapy for Patients With Advanced Non-small Cell Lung Cancer NCT03589950 | The First People's Hospital of Lianyungang | Phase 2 |
| Completed | Anlotinib in Metastatic HER2 Negative Breast Cancer NCT04002284 | Peng Yuan | Phase 2 |
| Unknown | Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma（RCC） NCT02072031 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 |